Company intelligence / Profile preview

AllerPops

Los Alamos, New Mexico, United Statesallerpops.com ↗

Ownership: Private
Development stage: Other

Overview

AllerPops has completed a randomized, double-blind, controlled Phase II clinical trial demonstrating significant improvement in nasal allergy symptoms with lasting relief for at least a week post-treatment. The product was found to be safe with minimal side effects. The company markets its prebiotic lollipops as an all-natural alternative to daily allergy medications or shots.

Therapeutic areas: RheumatologyImmunologyPulmonology
Modalities: Prebiotic therapyNon-pharmacological therapyLive biotherapeutic product therapy (by mechanism—modulating oral microbiota)
Industry: Biotech

Drug pipeline

4 assets

AllerPops

Unknown

3 more assets in the full pipeline.

Request access →

Partnerships

dicentra (Contract Research Organization partner for clinical trials)

Beyond the preview

Go deeper on AllerPops.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllerPops.

Explore the full profile